Imagion Biosystems is commercializing a form of medical imaging that uses biosafe nanoparticles to detect cancer, according to Proactive Investors Australia.
Imagion Biosystems President and CEO Bob Proulx told Proactive Investors Australia, "in the medical imaging space today there's no consumable that goes with it... with our technology, because it includes both the measuring instrument and an injectable component, there's the classic printer-ink business model. We think that will be attractive for our commercial partner because now you'll be able to not only sell and install and service the instrument, but you'll also have the consumable that goes with each of the new tests that we bring to market."
The company focuses on early detection and research for several types of cancer using nanoparticle diagnostic imaging technology.